Community pharmacist knowledge, attitudes and confidence regarding naloxone for overdose reversal

Addiction

Volumn 111, Issue 12, 2016, Pages 2177-2186

  Nielsen, Suzanne ^a,b   Menon, Nadia ^a   Larney, Sarah ^a   Farrell, Michael ^a   Degenhardt, Louisa ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b SOUTH EASTERN SYDNEY LOCAL HEALTH DISTRICT   (Australia)

Author keywords

Community pharmacy; naloxone; opioid; opioid antagonist; overdose; pharmacist

Indexed keywords

NALOXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST; NON PRESCRIPTION DRUG;

ADULT; AGED; ATTITUDE TO HEALTH; AUSTRALIA; CLINICAL COMPETENCE; DRUG OVERDOSE; FEMALE; HARM REDUCTION; HUMAN; MALE; MIDDLE AGED; PHARMACIST; PSYCHOLOGY; STANDARDS; YOUNG ADULT;

ADULT; AGED; ANALGESICS, OPIOID; AUSTRALIA; CLINICAL COMPETENCE; DRUG OVERDOSE; FEMALE; HARM REDUCTION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; NONPRESCRIPTION DRUGS; PHARMACISTS; YOUNG ADULT;

EID: 84994226079     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.13517     Document Type: Article

References (36)

1. Straus M. M., Ghitza U. E., Tai B. Preventing deaths from rising opioid overdose in the US—the promise of naloxone antidote in community-based naloxone take-home programs. Subst Abuse Rehabil 2013; 4: 65–72.
2. Clark A. K., Wilder C. M., Winstanley E. L. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med 2014; 8: 153–63.
3. Coffin P. O., Sullivan S. D. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med 2013; 158: 1–9.
4. Giglio R. E., Li G., DiMaggio C. J. Effectiveness of bystander naloxone administration and overdose education programs: a meta-analysis. Inj Epidemiol 2015; 2: 10.
5. Bennett A. S., Bell A., Tomedi L., Hulsey E. G., Kral A. H. Characteristics of an overdose prevention, response, and naloxone distribution program in Pittsburgh and Allegheny County, Pennsylvania. J Urban Health 2011; 88: 1020–30.
6. Walley A. Y., Xuan Z., Hackman H. H., Quinn E., Doe-Simkins M., Sorensen-Alawad A. et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ 2013; 346: f174.
7. Strang J., Manning V., Mayet S., Best D., Titherington E., Santana L. et al. Overdose training and take-home naloxone for opiate users: prospective cohort study of impact on knowledge and attitudes and subsequent management of overdoses. Addiction 2008; 103: 1648–57.
8. Matheson C., Bond C. M., Tinelli M. Community pharmacy harm reduction services for drug misusers: national service delivery and professional attitude development over a decade in Scotland. J Public Health 2007; 29: 350–57.
9. Sheridan J., Manning V., Ridge G., Mayet S., Strang J. Community pharmacies and the provision of opioid substitution services for drug misusers: changes in activity and attitudes of community pharmacists across England 1995–2005. Addiction 2007; 102: 1824–30.
10. Chaar B. B., Hanrahan J. R., Day C. Provision of opioid substitution therapy services in Australian pharmacies. Australas Med J 2011; 4: 210–6.
11. Hagemeier N. E., Alamian A., Murawski M. M., Pack R. P. Factors associated with provision of addiction treatment information by community pharmacists. J Subst Abuse Treat 2015; 52: 67–72.
12. Butler R., Sheridan J. Innocent parties or devious drug users: the views of primary healthcare practitioners with respect to those who misuse prescription drugs. Harm Reduct J 2010; 7: 21.
13. Matheson C., Thiruvothiyur M., Robertson H., Bond C. Community pharmacy drug misuse services over two decades in Scotland: implications for the future. Int J Drug Policy 2015; 27: 105–12.
14. Therapeutic Goods Association (TGA). Reasons for the scheduling delegate's interim decision and invitation for further comment for the ACMS. 1.2 Naloxone. Woden, ACT, Australia: TGA; 2015.
15. Pharmaceutical Society of Australia (PSA). Position Statement: Ethical Issues in Declining to Supply. Canberra: PSA; 2003.
16. Pharmaceutical Society of Australia. Code of Ethics for Pharmacists. Canberra: PSA; 2011.
17. Lenton S., Single E. The definition of harm reduction. Drug Alcohol Rev 1998; 17: 213–20.
18. Maven Marketing. Maven Marketing: List of Pharmacies and Chemists in Australia. 2012. Available at: http://www.mavenmarketing.com.au/list-of-pharmacies-in-australia/ (accessed 5 July 2012).
19. IBISWorld. IBISWorld Industry Report G4271a. Pharmacies in Australia. Melbourne, Australia: IBISWorld Network; 2015.
20. Edwards P. J., Roberts I., Clarke M. J., Diguiseppi C., Wentz R., Kwan I. et al. Methods to increase response to postal and electronic questionnaires. Cochrane Database Syst Rev 2009; Mr000008. DOI: 10.1002/14651858.MR000008.pub4.
21. Matheson C., Bond C. M., Mollison J. Attitudinal factors associated with community pharmacists' involvement in services for drug misusers. Addiction 1999; 94: 1349–59.
22. Green T. C., Mann M. R., Bowman S. E., Zaller N., Soto X., Gadea J. et al. How does use of a prescription monitoring program change pharmacy practice? J Am Pharm Assoc 2013; 53: 273–81.
23. Strang J., Powis B., Best D., Vingoe L., Griffiths P., Taylor C. et al. Preventing opiate overdose fatalities with take-home naloxone: pre-launch study of possible impact and acceptability. Addiction 1999; 94: 199–204.
24. Williams A. V., Strang J., Marsden J. Development of Opioid Overdose Knowledge (OOKS) and Attitudes (OOAS) Scales for take-home naloxone training evaluation. Drug Alcohol Depend 2013; 132: 383–86.
25. Watson T., Hughes C. Pharmacists and harm reduction: A review of current practices and attitudes. Can Pharm J 2012; 145: 124–7. e122.
26. Behar E., Santos G. M., Wheeler E., Rowe C., Coffin P. O. Brief overdose education is sufficient for naloxone distribution to opioid users. Drug Alcohol Depend 2015; 148: 209–12.
27. Robinson A., Wermeling D. P. Intranasal naloxone administration for treatment of opioid overdose. Am J Health Syst Pharm 2014; 71: 2129–35.
28. Lenton S. R., Dietze P. M., Degenhardt L., Darke S., Butler T. G. Naloxone for administration by peers in cases of heroin overdose. Med J Aust 2009; 191: 469.
29. Green T. C., Dauria E. F., Bratberg J., Davis C. S., Walley A. Y. Case study. Orienting patients to greater opioid safety: models of community pharmacy-based naloxone. Harm Reduct J 2015; 12: 25.
30. Beletsky L., Rich J. D., Walley A. Y. Prevention of fatal opioid overdose. JAMA 2012; 308: 1863–4.
31. Strang J., Kelleher M., Best D., Mayet S., Manning V. Emergency naloxone for heroin overdose. BMJ 2006; 333: 614–5.
32. Nielsen S., VanHout M. What is known about community pharmacy supply of naloxone? A scoping review. Int J Drug Policy 2016; 32: 24–33.
33. Green T. C., Dauria E. F., Bratberg J., Davis C. S., Walley A. Y. Orienting patients to greater opioid safety: models of community pharmacy-based naloxone. Harm Reduct J 2015; 12: 25.
34. Fenichel R. R. Which drugs should be available over the counter? The criteria are clear and include safety, timeliness, and opportunity cost. BMJ 2004; 329: 182–3.
35. Puspitasari H. P., Aslani P., Krass I. The influence of pharmacy and pharmacist characteristics on the secondary prevention of cardiovascular disease. Int J Clin Pharmacol 2015; 37: 834–43.
36. Australian Institute of Health and Welfare (AIHW). National Opioid Pharmacotherapy Statistics 2013, Drug treatment series no. 23. Cat. no. HSE 147. Canberra: AIHW; 2014.